Cardiff Oncology vs ImageneBio
ImageneBio reported revenue of $1 million in fiscal 2025, 1.3 times Cardiff Oncology's $1 million in fiscal 2025. Cardiff Oncology's revenue fell 13.2% in its latest year, and ImageneBio's fell 77.1%. Cardiff Oncology had an operating margin of -8256.3%, against -6056.4% at ImageneBio.
Side by side
| Cardiff Oncology | ImageneBio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $1M |
| Revenue growth | −13.2% | −77.1% |
| Revenue growth a year, last 5 years | 8.4% | −38.6% |
| Gross margin | — | — |
| Operating margin | −8,256.3% | −6,056.4% |
| Net margin | −7,732.0% | −5,668.6% |
| Free cash flow | −$38M | — |
| Free cash flow margin | −6,402.5% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 40.3% | 303.7% |
| Last close | $0.89 | $3.98 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.1 million, sold $0 | bought $95,840, sold $17,334 |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cardiff OncologyImageneBio
Operating margin
Percent of revenue
Cardiff OncologyImageneBio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cardiff OncologyImageneBio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cardiff Oncology and ImageneBio pages.